Hennion & Walsh Asset Management, Inc. Vertex Pharmaceuticals Inc Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.15 Billion
- Q1 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 6,795 shares of VRTX stock, worth $3.37 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
6,795
Previous 8,126
16.38%
Holding current value
$3.37 Million
Previous $3.27 Million
0.67%
% of portfolio
0.15%
Previous 0.16%
Shares
11 transactions
Others Institutions Holding VRTX
# of Institutions
1,773Shares Held
224MCall Options Held
1.63MPut Options Held
1.47M-
Capital World Investors Los Angeles, CA28.3MShares$14 Billion1.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.3MShares$11.5 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.6 Billion0.23% of portfolio
-
State Street Corp Boston, MA12MShares$5.94 Billion0.2% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.4MShares$5.17 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $127B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...